Evolus price target lowered to $18 from $21 at BTIG

BTIG analyst Sam Eiber lowered the firm’s price target on Evolus (EOLS) to $18 from $21 and keeps a Buy rating on the shares. Evolus reported a top-line Q2 miss, as Jeuveau sales declined for the first time in company history due to a softening U.S. aesthetic toxin market, the analyst tells investors in a research note. The management also noted they were beginning to see early signs of positive momentum early in Q3, with July incrementally better than the final two weeks of June, the firm is not expecting an immediate rebound, BTIG added.